{
    "eid": "2-s2.0-84906094507",
    "title": "Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study",
    "cover-date": "2014-01-01",
    "subject-areas": [
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [
        "Gemcitabine",
        "Hepatoma",
        "Sorafenib"
    ],
    "authors": [
        "Vichien Srimuninnimit"
    ],
    "citedby-count": 16,
    "ref-count": 17,
    "ref-list": [
        "Cancer Facts & Figures 2010",
        "Cancer incidence and mortality in France over the period 1978-2000",
        "Cancer statistics, 2005",
        "Design and endpoints of clinical trials in hepatocellular carcinoma",
        "Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference",
        "Systemic therapy for advanced hepatocellular carcinoma: Past, present, and future",
        "Sorafenib in advanced hepatocellular carcinoma",
        "Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial",
        "The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases",
        "Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): Results of a phase II study",
        "Gemcitabine plus Oxaliplatin for Patients with Advanced Hepatocellular Carcinoma Using Two Different Schedules",
        "Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.",
        "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial",
        "Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population",
        "Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma",
        "Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Bumrungrad International Hospital",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}